Progress and Remaining Opportunities to Increase the Use of Animal-free Antibodies in the USA

The scientific and ethical issues associated with the use of animal-derived antibodies in research can be overcome by the use of animal-free, sequence-defined recombinant antibodies, whose benefits are well documented. Here, we describe progress made following a 2019 expert meeting focused on improv...

Full description

Saved in:
Bibliographic Details
Published in:Alternatives to laboratory animals 2024-09, Vol.52 (5), p.285-289
Main Authors: Groff, Katherine, Allen, David, Casey, Warren, Clippinger, Amy J.
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c755-7c025d7bb0a9ca32d28f7f0a2fe207e3370c8cbfc4148915d64771ffd8f3054e3
container_end_page 289
container_issue 5
container_start_page 285
container_title Alternatives to laboratory animals
container_volume 52
creator Groff, Katherine
Allen, David
Casey, Warren
Clippinger, Amy J.
description The scientific and ethical issues associated with the use of animal-derived antibodies in research can be overcome by the use of animal-free, sequence-defined recombinant antibodies, whose benefits are well documented. Here, we describe progress made following a 2019 expert meeting focused on improving the quality and reproducibility of biomedical research by accelerating the production and use of animal-free recombinant antibodies in the USA. In the five intervening years since the meeting, participants have established multifaceted initiatives to tackle the next steps outlined during the meeting. These initiatives include: prioritising the replacement of ascites-derived and polyclonal antibodies; distributing educational materials describing recombinant antibodies; fostering public–private partnerships to increase access to recombinant antibodies; and increasing the availability of funding for recombinant antibody development. Given the widescale use of antibodies across scientific disciplines, a transition to modern antibody production methods relies on a commitment from government agencies, universities, industry and funding organisations, to initiatives such as those outlined here.
doi_str_mv 10.1177/02611929241266472
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3084030855</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3084030855</sourcerecordid><originalsourceid>FETCH-LOGICAL-c755-7c025d7bb0a9ca32d28f7f0a2fe207e3370c8cbfc4148915d64771ffd8f3054e3</originalsourceid><addsrcrecordid>eNplkEtLxDAUhYMoWMb5Ae6ydFPNo2nS5TD4GBgY0XEpJU1vxkAnqUm78N_bUnduzjlwPy6cg9AtJfeUSvlAWElpxSpWUFaWhWQXKGMlZzkXorpE2XzPZ-AarVNyDRGcK8mVyNDnawynCClh7Vv8BmftvPMnfOj7EIfRu8FBwkPAO28i6AR4-AL8MXmweOPdWXe5jQBTHlwT2pl2foHeNzfoyuouwfrPV-j49HjcvuT7w_Nuu9nnRgqRS0OYaGXTEF0ZzVnLlJWWaGaBEQmcS2KUaawpaKEqKtqpoqTWtspyIgrgK3S3vO1j-B4hDfXZJQNdpz2EMdWcqIJMIsSE0gU1MaQUwdZ9nErEn5qSeh6z_jcm_wX7TmY9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3084030855</pqid></control><display><type>article</type><title>Progress and Remaining Opportunities to Increase the Use of Animal-free Antibodies in the USA</title><source>Sage Journals Online</source><creator>Groff, Katherine ; Allen, David ; Casey, Warren ; Clippinger, Amy J.</creator><creatorcontrib>Groff, Katherine ; Allen, David ; Casey, Warren ; Clippinger, Amy J.</creatorcontrib><description>The scientific and ethical issues associated with the use of animal-derived antibodies in research can be overcome by the use of animal-free, sequence-defined recombinant antibodies, whose benefits are well documented. Here, we describe progress made following a 2019 expert meeting focused on improving the quality and reproducibility of biomedical research by accelerating the production and use of animal-free recombinant antibodies in the USA. In the five intervening years since the meeting, participants have established multifaceted initiatives to tackle the next steps outlined during the meeting. These initiatives include: prioritising the replacement of ascites-derived and polyclonal antibodies; distributing educational materials describing recombinant antibodies; fostering public–private partnerships to increase access to recombinant antibodies; and increasing the availability of funding for recombinant antibody development. Given the widescale use of antibodies across scientific disciplines, a transition to modern antibody production methods relies on a commitment from government agencies, universities, industry and funding organisations, to initiatives such as those outlined here.</description><identifier>ISSN: 0261-1929</identifier><identifier>EISSN: 2632-3559</identifier><identifier>DOI: 10.1177/02611929241266472</identifier><language>eng</language><ispartof>Alternatives to laboratory animals, 2024-09, Vol.52 (5), p.285-289</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c755-7c025d7bb0a9ca32d28f7f0a2fe207e3370c8cbfc4148915d64771ffd8f3054e3</cites><orcidid>0000-0002-0221-3080</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids></links><search><creatorcontrib>Groff, Katherine</creatorcontrib><creatorcontrib>Allen, David</creatorcontrib><creatorcontrib>Casey, Warren</creatorcontrib><creatorcontrib>Clippinger, Amy J.</creatorcontrib><title>Progress and Remaining Opportunities to Increase the Use of Animal-free Antibodies in the USA</title><title>Alternatives to laboratory animals</title><description>The scientific and ethical issues associated with the use of animal-derived antibodies in research can be overcome by the use of animal-free, sequence-defined recombinant antibodies, whose benefits are well documented. Here, we describe progress made following a 2019 expert meeting focused on improving the quality and reproducibility of biomedical research by accelerating the production and use of animal-free recombinant antibodies in the USA. In the five intervening years since the meeting, participants have established multifaceted initiatives to tackle the next steps outlined during the meeting. These initiatives include: prioritising the replacement of ascites-derived and polyclonal antibodies; distributing educational materials describing recombinant antibodies; fostering public–private partnerships to increase access to recombinant antibodies; and increasing the availability of funding for recombinant antibody development. Given the widescale use of antibodies across scientific disciplines, a transition to modern antibody production methods relies on a commitment from government agencies, universities, industry and funding organisations, to initiatives such as those outlined here.</description><issn>0261-1929</issn><issn>2632-3559</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNplkEtLxDAUhYMoWMb5Ae6ydFPNo2nS5TD4GBgY0XEpJU1vxkAnqUm78N_bUnduzjlwPy6cg9AtJfeUSvlAWElpxSpWUFaWhWQXKGMlZzkXorpE2XzPZ-AarVNyDRGcK8mVyNDnawynCClh7Vv8BmftvPMnfOj7EIfRu8FBwkPAO28i6AR4-AL8MXmweOPdWXe5jQBTHlwT2pl2foHeNzfoyuouwfrPV-j49HjcvuT7w_Nuu9nnRgqRS0OYaGXTEF0ZzVnLlJWWaGaBEQmcS2KUaawpaKEqKtqpoqTWtspyIgrgK3S3vO1j-B4hDfXZJQNdpz2EMdWcqIJMIsSE0gU1MaQUwdZ9nErEn5qSeh6z_jcm_wX7TmY9</recordid><startdate>202409</startdate><enddate>202409</enddate><creator>Groff, Katherine</creator><creator>Allen, David</creator><creator>Casey, Warren</creator><creator>Clippinger, Amy J.</creator><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0221-3080</orcidid></search><sort><creationdate>202409</creationdate><title>Progress and Remaining Opportunities to Increase the Use of Animal-free Antibodies in the USA</title><author>Groff, Katherine ; Allen, David ; Casey, Warren ; Clippinger, Amy J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c755-7c025d7bb0a9ca32d28f7f0a2fe207e3370c8cbfc4148915d64771ffd8f3054e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Groff, Katherine</creatorcontrib><creatorcontrib>Allen, David</creatorcontrib><creatorcontrib>Casey, Warren</creatorcontrib><creatorcontrib>Clippinger, Amy J.</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alternatives to laboratory animals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Groff, Katherine</au><au>Allen, David</au><au>Casey, Warren</au><au>Clippinger, Amy J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progress and Remaining Opportunities to Increase the Use of Animal-free Antibodies in the USA</atitle><jtitle>Alternatives to laboratory animals</jtitle><date>2024-09</date><risdate>2024</risdate><volume>52</volume><issue>5</issue><spage>285</spage><epage>289</epage><pages>285-289</pages><issn>0261-1929</issn><eissn>2632-3559</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>The scientific and ethical issues associated with the use of animal-derived antibodies in research can be overcome by the use of animal-free, sequence-defined recombinant antibodies, whose benefits are well documented. Here, we describe progress made following a 2019 expert meeting focused on improving the quality and reproducibility of biomedical research by accelerating the production and use of animal-free recombinant antibodies in the USA. In the five intervening years since the meeting, participants have established multifaceted initiatives to tackle the next steps outlined during the meeting. These initiatives include: prioritising the replacement of ascites-derived and polyclonal antibodies; distributing educational materials describing recombinant antibodies; fostering public–private partnerships to increase access to recombinant antibodies; and increasing the availability of funding for recombinant antibody development. Given the widescale use of antibodies across scientific disciplines, a transition to modern antibody production methods relies on a commitment from government agencies, universities, industry and funding organisations, to initiatives such as those outlined here.</abstract><doi>10.1177/02611929241266472</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-0221-3080</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0261-1929
ispartof Alternatives to laboratory animals, 2024-09, Vol.52 (5), p.285-289
issn 0261-1929
2632-3559
language eng
recordid cdi_proquest_miscellaneous_3084030855
source Sage Journals Online
title Progress and Remaining Opportunities to Increase the Use of Animal-free Antibodies in the USA
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T03%3A40%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progress%20and%20Remaining%20Opportunities%20to%20Increase%20the%20Use%20of%20Animal-free%20Antibodies%20in%20the%20USA&rft.jtitle=Alternatives%20to%20laboratory%20animals&rft.au=Groff,%20Katherine&rft.date=2024-09&rft.volume=52&rft.issue=5&rft.spage=285&rft.epage=289&rft.pages=285-289&rft.issn=0261-1929&rft.eissn=2632-3559&rft_id=info:doi/10.1177/02611929241266472&rft_dat=%3Cproquest_cross%3E3084030855%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c755-7c025d7bb0a9ca32d28f7f0a2fe207e3370c8cbfc4148915d64771ffd8f3054e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3084030855&rft_id=info:pmid/&rfr_iscdi=true